Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A First-in Man, Phase I Study Investigating the Safety and Tolerability of EP395 in Healthy Volunteers

Next Previous
Trial Profile

A First-in Man, Phase I Study Investigating the Safety and Tolerability of EP395 in Healthy Volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 28 Mar 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs EP 395 (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Adverse reactions; First in man
  • Sponsors EpiEndo Pharmaceuticals

Most Recent Events

  • 23 Mar 2022 Status changed from recruiting to completed.
  • 13 Apr 2021 According to EpiEndo Pharmaceuticals media release, the first subjects have been dosed in the Company's first-in-human phase I clinical trial of its lead candidate, EP395, at the Medicines Evaluation Unit (MEU) in Manchester, UK.The first six healthy subjects have been given a dose of EP395
  • 13 Apr 2021 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top